DermTech to Announce Fourth Quarter 2020 Financial Results on March 4, 2021
DermTech, Inc. (NASDAQ: DMTK) plans to release its fourth quarter 2020 financial results on March 4, 2021, after market close. A conference call will follow at 1:30 p.m. PT to discuss the results. Interested parties can join via phone or through a live webinar. DermTech focuses on precision dermatology, leveraging a non-invasive skin genomics platform for early skin cancer detection and treatment customization. The company aims to enhance dermatology care and improve patient outcomes. For additional details, visit investors.DermTech.com.
- DermTech is a leader in precision dermatology with a unique non-invasive skin genomics platform.
- The company markets products aimed at early detection of skin cancers.
- Future financial results are uncertain, with risks related to funding and market adoption.
- Current difficulties in obtaining reimbursement may hinder product adoption.
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its fourth quarter 2020 financial results after the market closes on Thursday, March 4, 2021. In conjunction with such release, DermTech plans to host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing (844) 467-7114 for domestic callers or (409) 231-2086 for international callers, using conference ID: 6588729. The live webinar for the call may be accessed by visiting the Events section on the Company's website at investors.DermTech.com. A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.
About DermTech:
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.
Forward-Looking Statements:
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness and commercialization of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10‑Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005083/en/
FAQ
When will DermTech release its fourth quarter 2020 financial results?
What time is the DermTech conference call scheduled on March 4, 2021?
How can I access the DermTech financial results webinar?
What is DermTech's focus in dermatology?
